Two-year clinical trial results from a Phase III study, announced by Regeneron Pharmaceuticals Inc., show that injection of 2 mg of Eylea aflibercept, in patients with diabetic macular edema dosed monthly or every two months (after 5 initial monthly injections), has a sustained improvement effect in best corrected visual acuity (BCVA), compared to laser photocoagulation. The study showed that following two years of treatment on a monthly basis, patients had a mean change from baseline in BCVA of 11.5 letters (versus 12.5 letters at 52 weeks) while patients receiving injections every second month (following a pre-loading regiment) had a mean change from baseline in BCVA of 11.1 letters (versus 10.7 letters at 52 weeks). In comparison, patients in the laser photocoagulation treatment group had a mean change from baseline in BCVA of 0.9 letters (versus 0.2 letters at 52 weeks).
Two-year Phase III data indicates that VEGF Trap-Eye (Eylea aflibercept) has sustained benefit in treatment of diabetic macular edema (DME)
- by swdadmin